Physician profile
Rima Youssef
NPI 1922821313
$1,518.72
in general payments reported to CMS, 2019-2025
18 companies · $1,454 in 2025
The $1,454 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $64.34 · 2025: $1,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,518.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $299.49 | 2025 | Ozempic |
| Amgen INC. | $223.87 | 2024-2025 | Tepezza, Repatha |
| Xeris Pharmaceuticals, INC. | $142.91 | 2025 | Recorlev |
| Sequel Med Tech, LLC | $123.52 | 2025 | Twiist |
| Lilly USA, LLC | $92.02 | 2025 | Zepbound, Mounjaro |
| Neurocrine Biosciences, INC. | $89.26 | 2025 | |
| Corcept Therapeutics | $86.20 | 2024-2025 | Korlym |
| Dexcom, INC. | $84.70 | 2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $76.18 | 2025 | Minimed 780g |
| Antares Pharma, INC. | $67.90 | 2024-2025 | Xyosted |
| Madrigal Pharmaceuticals | $61.82 | 2025 | Rezdiffra |
| Verity Pharmaceuticals INC. | $37.79 | 2024-2025 | Tlando |
| Tandem Diabetes Care, INC. | $33.83 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $22.96 | 2025 | |
| Kyowa Kirin, INC. | $19.84 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $19.52 | 2025 | Mycapssa |
| Ascendis Pharma Endocrinology INC | $19.12 | 2025 | Yorvipath |
| Tolmar, INC. | $17.79 | 2025 | Fensolvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rima Youssef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.